1. Scrip
  2. >>Digital Technologies
  3. >>AI

Amgen Joins AI/ML Gold Rush With Generate Deal

 
• By Alaric DeArment

Deal Snapshot: At a same-day conference, Amgen’s CEO outlined the importance of AI/ML to the company’s drug development strategy, as numerous large biopharma companies have recently made similar deals.

AI hand reaches
Amgen and Generate announced a deal worth potentially $1.9bn focused on AI/ML in drug development • Source: Shutterstock

Who: Amgen, Inc.; Generate Biomedicines

What: Amgen and Flagship Pioneering-backed Generate announced a deal 6 January across different disease areas and modalities, using Generate’s artificial intelligence and

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from AI

More from Digital Technologies